首页> 美国卫生研究院文献>Blood >Hematopoiesis and Stem Cells: Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation
【2h】

Hematopoiesis and Stem Cells: Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation

机译:造血和干细胞:通过NOD / SCID移植检测血管生成素样5和IGFBP2刺激人脐血造血干细胞的离体扩增

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hematopoietic stem cells (HSCs) are the basis of bone marrow transplantation and are attractive target cells for hematopoietic gene therapy, but these important clinical applications have been severely hampered by difficulties in ex vivo expansion of HSCs. In particular, the use of cord blood for adult transplantation is greatly limited by the number of HSCs. Previously we identified angiopoietin-like proteins and IGF-binding protein 2 (IGFBP2) as new hormones that, together with other factors, can expand mouse bone marrow HSCs in culture. Here, we measure the activity of multipotent human severe combined immunodeficient (SCID)–repopulating cells (SRCs) by transplantation into the nonobese diabetic SCID (NOD/SCID) mice; secondary transplantation was performed to evaluate the self-renewal potential of SRCs. A serum-free medium containing SCF, TPO, and FGF-1 or Flt3-L cannot significantly support expansion of the SRCs present in human cord blood CD133+ cells. Addition of either angiopoietin-like 5 or IGF-binding protein 2 to the cultures led to a sizable expansion of HSC numbers, as assayed by NOD/SCID transplantation. A serum-free culture containing SCF, TPO, FGF-1, angiopoietin-like 5, and IGFBP2 supports an approximately 20-fold net expansion of repopulating human cord blood HSCs, a number potentially applicable to several clinical processes including HSC transplantation.
机译:造血干细胞(HSC)是骨髓移植的基础,并且是造血基因治疗的诱人靶细胞,但是这些重要的临床应用受到HSC体外扩增困难的严重阻碍。特别地,脐带血用于成人移植的用途受到HSC数量的极大限制。以前,我们将血管生成素样蛋白和IGF结合蛋白2(IGFBP2)识别为新激素,与其他因素一起可以扩大培养小鼠骨髓HSC的水平。在这里,我们通过移植到非肥胖型糖尿病SCID(NOD / SCID)小鼠中来测量多能性人类严重联合免疫缺陷(SCID)再生细胞(SRC)的活性;进行二次移植以评估SRC的自我更新潜力。含有SCF,TPO和FGF-1或Flt3-L的无血清培养基不能明显支持人脐带血CD133 + 细胞中存在的SRC的扩增。如通过NOD / SCID移植测定的,向培养物中添加血管生成素样5或IGF结合蛋白2导致HSC数目的大量增加。包含SCF,TPO,FGF-1,血管生成素样5和IGFBP2的无血清培养物支持重提人脐带血HSC的大约20倍净扩展,许多可能适用于包括HSC移植在内的几种临床过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号